To identify clinical and therapeutic features of pulmonary nontuberculous mycobacterial (PNTM) disease, we conducted a retrospective analysis of patients referred to the Brazilian reference center, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil, who received a diagnosis of PNTM during 1993–2011 with at least 1 respiratory culture positive for NTM. Associated conditions included bronchiectasis (21.8%), chronic obstructive pulmonary disease (20.7%), cardiovascular disease (15.5%), AIDS (9.8%), diabetes
(9.8%), and hepatitis C (4.6%). Two patients had Hansen
disease; 1 had Marfan syndrome. Four mycobacterial spe-
cies comprised 85.6% of NTM infections: *Mycobacterium
kansasii*, 59 cases (33.9%); *M. avium* complex, 53 (30.4%); *M. abscessus*, 23 (13.2%); and *M. fortuitum*, 14 (8.0%).
A total of 42 (24.1%) cases were associated with rapidly
growing mycobacteria. In countries with a high prevalence
of tuberculosis, PNTM is likely misdiagnosed as tuberculo-
sis, thus showing the need for improved capacity to diag-
nose mycobacterial disease as well as greater awareness
of PNTM disease prevalence.

Pulmonary disease caused by nontuberculous mycobac-
teria (PNTM) frequently causes sickness and death.
These bacteria are found in water sources and soil and are
particularly concentrated in biofilms (1,2). Certain clinical
conditions are known to be associated with an increased
risk of PNTM, particularly immunosuppressive conditions
and structural changes in the lung, such as those associ-
ated with chronic obstructive pulmonary disease (COPD),
bronchiectasis, sequelae from prior pulmonary tuberculosis
(TB), and cystic fibrosis (3).

Recent studies have documented the emergence of
NTM lung diseases in industrialized countries, such as
the United States (4,5). The current prevalence estimated
for PNTM is ≈6 cases/100,000 population, with the high-
est prevalence in persons >50 years of age (4–6). In many
developing countries with a high prevalence of TB, the
prevalence of PNTM among immunocompetent persons
remains unknown, largely because of the lack of routine
culture and species identification from samples of persons
with suspected cases. In Brazil in 2010, 70,601 cases of TB
were reported, indicating a prevalence of 38 cases/100,000
population. In the same year, 4,500 deaths from TB were
reported. In 2011, TB was the third leading cause of death
(from infectious diseases) and the first among AIDS pa-
tients, according to surveillance data from Brazil’s Na-
tional TB Control Program (7). However, because TB is
routinely diagnosed presumptively, solely on the basis of
identifying acid-fast bacilli (AFB) from sputum samples,
an unknown proportion of patients may in fact be infected
with NTM. Therefore, the true prevalence of NTM in Bra-
zil remains unknown.

In Brazil, the Professor Helio Fraga Reference Center
(CRPHF) has served as a reference center for multidrug-
resistant TB (MDR TB) and NTM since 1993. From 1993
to 2011, 5,638 cases of MDR TB were reported in Brazil,
1,894 of them in Rio de Janeiro; 1,595 of these patients
were treated at CRPHF (8).

Prior studies have described some of the features of
clinical isolates from PNTM patients (9–14), and others
have described the clinical features for small populations
infected with NTM clinical isolates in Brazil (15,16). To
more fully describe the emerging prevalence and associ-
ated conditions of PNTM in a large urban population in
Brazil, we present results of a large and detailed review
of PNTM case-patients with PNTM who were treated
at CRPHF.

Materials and Methods

Referral Population

CRPHF is a national reference center for the diagnosis
and treatment of MDR TB, and it also functions as a lo-
cal reference center for treatment of PNTM case-patients
from Rio de Janeiro through an outpatient unit. In Brazil,
mycobacterial cultures are only performed for specific
groups: 1) patients newly diagnosed with TB who remain
positive for AFB positive in the second month of treatment;
2) patients who have a history of prior treatment for TB
and are newly AFB positive; 3) patients who are contacts
of persons with drug-resistant TB; and 4) patients who are
part of specific population groups, including health profes-
sionals, the homeless, prisoners, indigenous populations,
and HIV-positive persons (7). Thus, patients are referred
to CRPHF from public and private healthcare facilities for
mycobacterial species identification when NTM or MDR
TB is suspected, typically because the patients remain AFB
positive and do not improve clinically while receiving TB
treatment, or when 1 sample culture is positive for NTM
with no species identified. Radiographic evaluations are
performed at baseline and at follow-up visits through x-ray
films or, more recently, computed tomographic scans.

Study Population and Data Collection

The study population comprised patients from the state
of Rio de Janeiro who were referred to CRPHF for further
evaluation, for either PNTM or MDR TB. Patients includ-
ed in this analysis had at least 1 respiratory isolate identi-
fied as NTM, were residents in the state of Rio de Janeiro,
and were referred to CRPHF during January 1993–January
2011. Only patients with NTM isolated from respiratory
specimens were included. Demographic, clinical, and epi-
demiologic information was collected from patient clini-
cal records. Information included co-existing conditions,
smoking history, and results of radiographic imaging. With
respect to microbiologic information, data included treat-
ment duration for NTM disease, month of the first negative
sputum culture, and treatment outcome. Additional infor-
mation included the number of prior episodes of TB and
prior treatment for TB, including information about those
who had been treated for TB for at least 6 months before
the diagnosis of NTM disease. Microbiologic confirma-
tion with sputum culture and species identification were
not able to be carried out for samples from patients’ prior
TB episodes.
Nontuberculous Mycobacterial Disease, Brazil

Treatment and Assessment of Microbiologic Response

After a patient’s diagnosis at CRPHF, sputum samples are collected monthly or bimonthly until treatment is completed. Subsequently, sputum samples are collected every 3 months in the first 12 months following treatment, and then every 6 months for at least 2 years following treatment. Recommended treatment depends on species, and generally follows American Thoracic Society (ATS) guidelines (3), with a course of 12–18 months for slow-growing mycobacteria, such as M. kansasii or M. avium complex (MAC), and longer courses for rapidly growing mycobacteria. The definitions for classification of treatment response were as follows: 1) cure was indicated by at least 3 consecutive respiratory specimens negative for NTM during 12 consecutive months; 2) treatment failure was indicated by at least 2 positive cultures at the end of 12 months of treatment; 3) relapse was indicated by cultures positive for NTM >30 days after a prior cure; and 4) death meant death from any cause during treatment, regardless of whether death was confirmed as associated with NTM disease.

Laboratory Methods

Before 2004, species identification for M. kansasii, MAC, M. abscessus, and M. fortuitum was done through biochemical tests. Subsequently, the hsp65 PCR restriction analysis (PRA) method was used for species identification.

Data Analysis

To assess association of species and cavitary disease with culture conversion, we used Epi Info version 3.5.3 (www.cdc.gov/epiinfo/) and SAS version 9.2 (SAS Institute Inc., Cary, NC, USA). The significance of associations was assessed by using χ² with p<0.05. We limited this analysis to those patients who met the ATS criteria (>1 NTM-positive sputum sample or 1 sample from bronchoalveolar lavage or lung biopsy specimens).

Results

Demographic and Clinical Features of Patients with NTM Lung Disease

We identified a total of 174 patients in our study population; 108 (62.1%) were male. The median age was 55 years (range 24–86 years). Smoking history was available for 153 patients, of whom 95 (62.1%) reported past or current smoking. The most frequent symptoms were respiratory (60.9%), but 30.5% of the total patients had both respiratory and systemic symptoms (fever, weight loss). The definitions for classification of treatment response were as follows: 1) cure was indicated by at least 3 consecutive respiratory specimens negative for NTM during 12 consecutive months; 2) treatment failure was indicated by at least 2 positive cultures at the end of 12 months of treatment; 3) relapse was indicated by cultures positive for NTM >30 days after a prior cure; and 4) death meant death from any cause during treatment, regardless of whether death was confirmed as associated with NTM disease.
respiratory and systemic symptoms, including cough, dyspnea, hemoptysis, thoracic pain, fever, weight loss, and night sweats (Table 1). Overall, 101 (58.0%) patients reported prior treatment for TB, based on only a positive AFB smear (without microbiologic confirmation for M. tuberculosis), of whom 80 (79%) were referred while being treated empirically for TB for up to 6 months before the diagnosis of NTM infection. Overall, 127 (72.9%) patients met the ATS criteria for NTM disease (Table 1). The number of PNTM cases identified from 1993 to 2005 ranged from 5 to 7 cases per year. However, beginning in 2006, the number of identified cases reached ≈20, and it has remained at 20–40 cases per year since then (Figure).

With respect to coexisting conditions, 59 (33.9%) patients had no identified coexisting conditions. The most frequently identified conditions were bronchiectasis (21.8%), COPD (20.7%), and cardiovascular disease (15.5%). A lower proportion of patients were identified with AIDS (9.8%), diabetes (9.8%), and hepatitis C (4.6%). All patients with bronchiectasis had this condition identified through computed tomographic scans. Two patients had Hansen disease, 1 of whom also had hepatitis C. One patient had Marfan syndrome and no other reported coexisting conditions (Table 2). Patients may have had >1 coexisting condition.

Patients without prior treatment for TB were not significantly different from those with prior treatment with respect to age, sex, infecting species, or clinical features. Among the 73 patients with no prior TB treatment, 47 (64.4%) were male with a mean age of 54 years. In this group, 43 (58.9%) showed cavitary lesions, of which 29 (67.4%) were bilateral.

### Table 2. Coexisting medical conditions for 174 patients with PNTM, Brazil, 1993–2011

<table>
<thead>
<tr>
<th>Coexisting condition†</th>
<th>No. (%) patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>None</td>
<td>59 (33.9)</td>
</tr>
<tr>
<td>Bronchiectasis</td>
<td>38 (21.8)</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease</td>
<td>36 (20.7)</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>27 (15.5)</td>
</tr>
<tr>
<td>AIDS</td>
<td>17 (9.8)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>17 (9.8)</td>
</tr>
<tr>
<td>Asthma</td>
<td>8 (4.6)</td>
</tr>
<tr>
<td>Hepatitis C</td>
<td>8 (4.6)</td>
</tr>
<tr>
<td>Cancer, excluding lung cancer</td>
<td>6 (3.4)</td>
</tr>
<tr>
<td>Gastroesophageal reflux</td>
<td>6 (3.4)</td>
</tr>
<tr>
<td>Rheumatoid arthritis</td>
<td>3 (1.7)</td>
</tr>
<tr>
<td>Nonviral cirrhosis</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Hansen disease</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Lupus</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>Anemia falciforme</td>
<td>1 (0.57)</td>
</tr>
<tr>
<td>Silicosis</td>
<td>1 (0.57)</td>
</tr>
<tr>
<td>Marfan syndrome</td>
<td>1 (0.57)</td>
</tr>
<tr>
<td>Kidney transplantation and immunosupression</td>
<td>1 (0.57)</td>
</tr>
<tr>
<td>Mitral valve prolapse</td>
<td>1 (0.57)</td>
</tr>
</tbody>
</table>

*PNTM, pulmonary nontuberculous mycobacterial disease.
†Patients may have exhibited >1 coexisting condition.

### Table 3. Mycobacterium species infecting 174 patients with PNTM, Brazil, 1993–2011

<table>
<thead>
<tr>
<th>Species</th>
<th>No. (%) patients infected</th>
</tr>
</thead>
<tbody>
<tr>
<td>M. kansasii</td>
<td>59 (33.9)</td>
</tr>
<tr>
<td>Mycobacterium avium complex</td>
<td>53 (30.4)</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>23 (13.2)</td>
</tr>
<tr>
<td>M. fortuitum</td>
<td>14 (8.0)</td>
</tr>
<tr>
<td>M. massiliense</td>
<td>3 (1.7)</td>
</tr>
<tr>
<td>M. peregrinum</td>
<td>2 (1.1)</td>
</tr>
<tr>
<td>M. asiaticum</td>
<td>1 (0.57)</td>
</tr>
<tr>
<td>M. simiae</td>
<td>1 (0.57)</td>
</tr>
<tr>
<td>M. lentiflavum</td>
<td>1 (0.57)</td>
</tr>
<tr>
<td>M. szulgai</td>
<td>1 (0.57)</td>
</tr>
<tr>
<td>M. celatum</td>
<td>1 (0.57)</td>
</tr>
<tr>
<td>M. terrae</td>
<td>1 (0.57)</td>
</tr>
<tr>
<td>Not identified</td>
<td>14 (8.0)</td>
</tr>
</tbody>
</table>

*PNTM, pulmonary nontuberculous mycobacterial disease.

### Species Identification and Response to Treatment

Four species comprised 85.6% of all species identified: M. kansasii, 33.9%, MAC, 30.4%, M. abscessus, 13.2%, and M. fortuitum, 8.0%. Overall, 42 (24.1%) patients had an isolate identified as a rapidly growing mycobacterium (M. fortuitum, M. abscessus, M. peregrinum, M. massiliense) (Table 3). The proportion of species identified through PRA was as follows: M. kansasii, 69.5%; MAC, 62.3%; M. abscessus, 55.5%; M. fortuitum, 57.1%; all other species, 100%. The species distribution in the group of patients with prior treatment for TB was similar to the overall distribution, with 37.3% infected with M. kansasii and 26.6% infected with MAC. The species distribution in the group of patients with bronchiectasis also showed a similar distribution: M. kansasii was the most frequent (31.5%), followed by MAC (31.5%), M. abscessus (10.5%), and M. massiliense (5.2%). Infection with uncommon species, such as M. simiae, M. lentiflavum, M. celatum, and M. szulgai, all occurred in this group.

Treatment outcome varied significantly by infecting species, with the highest cure rate (71.4%) observed among patients infected with M. kansasii, followed by those infected with MAC (57.8%), and the lowest cure rate (25.0%) was observed in patients infected with M. abscessus (Table 4). Although the majority of patients had cavitary disease, among those infected with M. kansasii, the outcome of disease was similar for those with cavitary and noncavitary lesions (72.7% and 67.0%, respectively); among those infected with MAC or M. abscessus, the cure rates appeared somewhat higher for those with noncavitary disease, although this effect was not significant (Table 5).

Treatment regimens by infecting species are shown in Table 6. Of the patients with MAC infection, 54.7% received combination antimicrobial drug therapy, consisting of rifampin, ethambutol, and clarithromycin; 52.0% of patients infected with M. kansasii underwent regimens containing rifampin, ethambutol, and isoniazid. Infections...
of patients with rapidly growing mycobacteria were treated with clarithromycin in combination with amikacin.

Discussion

We report the emergence of PNTM among patients receiving care at a referral center for MDR TB. Although we were unable to determine the true prevalence of disease caused by these organisms in the state of Rio de Janeiro, the current study confirmed an increasing frequency of patients referred with NTM lung disease. In some industrialized countries, the prevalence of NTM has been found to be increasing (5,17), although it remains unclear whether this increase is related to increasing awareness of physicians that leads to more frequent diagnosis, to improved laboratory capacity, or to a combination of both factors.

Brazil has a high prevalence of TB, so initial the treatment for TB is based on smear results; culturing is not done and species is not identified before treatment. Thus, patients infected with slowly growing mycobacteria (e.g., M. kansasi), which have a pulmonary manifestation similar to that of M. tuberculosis and might respond to empirical treatment with anti-TB drugs, may not have received an appropriate diagnosis. A notable limitation of this study is that we could not accurately determine whether these patients were truly infected with M. tuberculosis and had NTM disease as a sequela of their TB disease, or if they were initially infected with NTM. Because empirical treatment is not appropriate for those with M. tuberculosis infections, but is done in many parts of the world due to lack of resources, strengthened laboratory capacity is needed to correctly identify the prevalence of emerging NTM disease (18). Given the lack of capacity for culture confirmation of all cases of TB, the current disease effects of NTM are likely underestimated in Brazil as well as in other countries with similar resource limitations for mycobacterial diagnostics. The introduction of more affordable rapid diagnostic tools to improve diagnostic capacity should reduce potential misdiagnosis to better estimate the true extent of PNTM.

One third of the NTM patients in this study population were infected with M. kansasi, a proportion substantially higher than that seen in the United States (5,19) and in other areas of Brazil (10,14) and Australia (20). Global geographic variability in M. kansasi has been noted; a high prevalence of M. kansasi lung disease occurs in Western Europe, Switzerland, and the United Kingdom (17,21–23). In Brazil, available data suggest regional differences in species distribution, although distinct study populations and methods limit comparability of estimates. A prior report from CRPHF, analyzing samples sent from throughout Brazil during 1994–1999, found that of 433 pulmonary isolates, 203 (46.9%) were MAC and 61 (14.0%) were M. kansasi. In that study, some regional variability in the relative proportions of M. kansasi and MAC was evident, with a somewhat lower proportion of M. kansasi in the Southeast (18%) and South regions (13.7%) relative to the North (24.3%) (24). Other studies conducted in different areas of Brazil have found that M. kansasi infections range from 16.0% in Bahia (15) to 2.2% in São Paulo (12) and 0% in the northern Amazonian region (9). For M. kansasi, municipal water systems are the primary source of M. kansasi; thus, the degree of urbanization is likely to affect isolation rates. Climatic and ecological factors as well as the prevalence of cofactors, such as HIV infection, are also likely to influence the prevalence of NTM species. Brazil encompasses a wide geographic area with large variations in climatic conditions and urbanization. We cannot sort out these factors in our analysis, and future research is needed to address these issues.

M. kansasi infection is manifested as a lung disease that is nearly identical to TB with a high prevalence of cavities and a predominance of fibrocavitary lesions in the

---

Table 4. Cure rates by species infecting patients with ATS-defined PNTM, Brazil, 1993–2011*

<table>
<thead>
<tr>
<th>Species</th>
<th>No. (%) patients</th>
<th>Total no.</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>cured</td>
<td></td>
</tr>
<tr>
<td>Mycobacterium kansasi</td>
<td>30 (71.4)</td>
<td>42</td>
</tr>
<tr>
<td>M. avium complex</td>
<td>26 (57.9)</td>
<td>45</td>
</tr>
<tr>
<td>M. abscessus</td>
<td>6 (25.0)</td>
<td>24</td>
</tr>
<tr>
<td>M. fortuitum</td>
<td>5 (45.4)</td>
<td>11</td>
</tr>
<tr>
<td>Other</td>
<td>2 (40.0)</td>
<td>5</td>
</tr>
<tr>
<td>Total</td>
<td>69 (54.3)</td>
<td>127</td>
</tr>
</tbody>
</table>

*ATS, American Thoracic Society; PNTM, pulmonary nontuberculous mycobacterial disease. Patients without identified species were excluded from this analysis.

Table 5. Association of cavitary disease with cure rates of patients with ATS-defined PNTM, Brazil, 1993–2011*

<table>
<thead>
<tr>
<th>Species</th>
<th>No. (%) patients</th>
<th>Relative risk (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>With noncavitary disease</td>
<td>With cavitary disease</td>
</tr>
<tr>
<td>Mycobacterium kansasi</td>
<td>6 (67)</td>
<td>24 (72.7)</td>
</tr>
<tr>
<td>Cure</td>
<td>9</td>
<td>33</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M. avium complex</td>
<td>12 (85.7)</td>
<td>14 (45.2)</td>
</tr>
<tr>
<td>Cure</td>
<td>14</td>
<td>31</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
<tr>
<td>M. abscessus</td>
<td>3 (42.9)</td>
<td>3 (17.7)</td>
</tr>
<tr>
<td>Cure</td>
<td>7</td>
<td>14</td>
</tr>
<tr>
<td>Total</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*ATS, American Thoracic Society; PNTM, pulmonary nontuberculous mycobacterial disease.
...infected with disease was an underlying medical problem in patients infected with hepatitis C, 5 had various degrees of hepatic fibrosis). Of the 8 case-patients patients had hepatitis C (from different genotypes and with has been found in the United States (3). However, more recent studies have found a lower frequency of cavitary lesions associated with M. kansasii infection in Korea (32%) (25) and Israel (57%) (26). A culture conversion rate of 95% was found from the study in Korea, with conversion defined as 3 negative samples within a 6-month period (25).

In our study, approximately one quarter of patients had no coexisting condition, and 40% had no prior history of TB treatment. NTM have historically been associated with disease in male smokers with COPD (27). However, over the last 20 years, the epidemiology has been changing in some industrialized countries, particularly the United States, with most patients identified without known risk factors or with bronchiectasis, all in the context of declining rates of TB (5,6).

The finding from this study of 1 patient with Marfan syndrome and 1 patient with mitral valve prolapse is consistent with the association of predisposing genetic disorders of the connective tissue with a certain morphotype, as has been found in in the United States (28). In our cohort, 8 patients had hepatitis C (from different genotypes and with various degrees of hepatic fibrosis). Of the 8 case-patients with hepatitis C, 5 had M. kansasii infection, and the 2 other patients with noncirrhotic the liver were also infected with M. kansasii. Another study found chronic liver disease was an underlying medical problem in patients infected with M. kansasii (26).

In summary, in Brazil, a country with a high prevalence of TB, the misdiagnosis of NTM disease may lead to inaccurate and inappropriate treatment. This study suggests that despite the high level of TB in Brazil, subpopulations of patients with NTM exist, and these infections are not being adequately detected and treated. Continued monitoring of PNTM is needed in Brazil, and more detailed information should be obtained on pulmonary disease resulting from these infections, including their regional distribution, species, associated coexisting conditions, and treatment response. In addition, adequate laboratory infrastructure and affordable testing are needed at the local level to ensure accurate diagnosis and proper treatment for all.

Acknowledgments

We thank the out-patient unit staff and patients from CRPHF/Escola Nacional de Saude Publica/Oswaldo Cruz Foundation who made this study possible.

This study was supported in part by funds from the Osvaldo Cruz Foundation and in part by the Division of Intramural Research of the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA. F.C.Q.M. was supported by Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (project no. 303777/2010-9) and by Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro (project nos. E-26/111.497/2008 and E-26/103.225/2011).

Dr Couto de Mello is a physician at the Reference Center Professor Helio Fraga in Rio de Janeiro and completed this work as part of her master’s thesis at the Federal University of Rio de Janeiro. Her research interests include the epidemiology and clinical characteristics of nontuberculous pulmonary diseases.

References


Table 6. Treatment regimens for all patients with ATS-defined PNTM, per infecting species, Brazil, 1993–2011*

<table>
<thead>
<tr>
<th>Species</th>
<th>Treatment regimen (%)†‡</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Mycobacterium avium</em> complex</td>
<td>Clarithromycin, amikacin, ethambutol, rifampin (54.7)</td>
</tr>
<tr>
<td></td>
<td>Clarithromycin, ethambutol, quinolone, terizidon (28.3)</td>
</tr>
<tr>
<td></td>
<td>Clarithromycin, amikacin, ethambutol, quinolone (7.0)</td>
</tr>
<tr>
<td><em>Mycobacterium kansasii</em></td>
<td>Rifampin, ethambutol, isoniazid (52.5)</td>
</tr>
<tr>
<td></td>
<td>Clarithromycin, amikacin, terizidon (68.4)</td>
</tr>
<tr>
<td></td>
<td>Clarithromycin, amikacin, doxycycline (10.5)</td>
</tr>
<tr>
<td></td>
<td>Clarithromycin, amikacin, tigeciclin (33.3)</td>
</tr>
<tr>
<td><em>M. abscessus</em></td>
<td>Clarithromycin, amikacin (33.3)</td>
</tr>
<tr>
<td></td>
<td>Clarithromycin, amikacin, doxycycline (33.3)</td>
</tr>
<tr>
<td></td>
<td>Clarithromycin, amikacin, tigeciclin (33.3)</td>
</tr>
<tr>
<td><em>M. massiliense</em></td>
<td>Clarithromycin, amikacin (64.2)</td>
</tr>
<tr>
<td></td>
<td>Clarithromycin, amikacin, rifampin (28.5)</td>
</tr>
<tr>
<td></td>
<td>Clarithromycin, amikacin, quinolone, doxycycline (7.3)</td>
</tr>
</tbody>
</table>

*ATS, American Thoracic Society; PNTM, pulmonary nontuberculous mycobacterial disease.
†Median duration of treatment, 19 mo.
‡Quinolones: levofloxacin, ciprofloxacin, moxifloxacin, ofloxacin.

...for all.


Address for correspondence: Margareth Pretti Dalcolmo, Estrada do Curicica 2000, Curicica Rio de Janeiro, RJ, CEP 21045900, Brazil; email: margarethdalcolmo@terra.com.br